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List of abbreviations 
∆A  Absorbance 
AT-1  Antithrombin-1 
AT-3  Antithrombin-3 
Ca2+  Calcium ions 
CAT  Calibrated Automated Thrombography 
CD11b  Cluster Determinant 11b (membrane receptor) 
CRT  Coagulation Reaction Time  
CS  Chromogenic Substrate 
DIC   Disseminated Intravascular Coagulation 
EXCA  Extrinsic Coagulation Activity Assay 
F  Coagulation factor 
IC  Inhibitory Concentration 
IL  Interleukin 
INCA  Intrinsic Coagulation Activity Assay 
IU  International Units 
K  Kallikrein 
kDa  KiloDalton 
LMWH  Low Molecular Weight Heparin 
LPS  Lipopolysaccharide 
MØ  Monocyte 
Min  Minutes 
MV  Mean Value 
MW  Molecular Weight 
NIC  Normal Intravascular Coagulation 
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PIC  Pathological Intravascular Coagulation 
PK  Prekallikrein 
PL  Phospholipids 
PMN  Polymorphonuclear Neutrophil Granulocyte 
PTT  Partial Thromboplastin Time 
RECA  Recalcified Coagulation Activity Assay 
SC  Stimulatory Concentration 
SD  Standard Deviation 
Serpin  Serine Protease Inhibitor 
TF  Tissue Factor 
 
Coagulation factors are expressed in Arabic numbers. In figures they may also be 
expressed in Roman numbers. 
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1.1.  German Abstract 
In der vorliegenden Arbeit wurde untersucht, wie die Blutgerinnung durch das in der 
Klinik oft verwendete Aminoglykosid-Antibiotikum Gentamicin (Gentamicin⋅H2SO4) 
beeinflusst wird. Die Grundüberlegung ist, dass Gentamicin als potentes 
Breitspektrum-Antibiotikum oft in lebensbedrohlichen, septischen Zuständen 
eingesetzt wird, in denen die physiologische Blutgerinnung bereits beeinträchtigt ist, 
im Sinne einer pathologischen, disseminierten, intravasalen Koagulopathie. Hier wurde 
untersucht, wie Gentamicin sich auf die Generierung des wichtigsten Enzyms der 
Hämostase, Thrombin, auswirkt. Dafür wurden 139 individuelle Citrat-Plasmaproben 
und 11 Citrat-Plasmapools gesunder Probanden verwendet. 50 µl Proben wurden mit 
Gentamicin in der klinisch relevanten Konzentration von 0-19.6 mg/l in 
Mikrotiterplatten supplementiert. Das Citrat-Plasma wurde unmittelbar danach 
rekalzifiert und das in der Gerinnungsreaktions-Zeit (coagulation reaction time = CRT) 
entstandene Thrombin im ultra-sensitiven, ultra spezifischen RECA (recalcified 
coagulation activity assay) quantifiziert. Diejenige plasmatische Gentamicin-
Konzentration, welche die intrinsische Thrombin-Generierung ca. zweifach stimuliert, 
also die klinisch-relevante approx. SC200 (approximate 200% stimulatory 
concentration), wurde in der Gentamicin-Konzentration vs. Thrombin-Generierungs-
Graphik ermittelt. 5 normale Plasmen wurden auch nach Zugabe von 
0.5 IU/ml niedermolekularem Heparin untersucht. Bei der Auswertung zeigten 
130 von 139 individuellen normalen Plasmaproben (94%) eine durch Gentamicin 
zweifach verstärkte Thrombingenerierung im Konzentrationsbereich von 
2.0 ± 2.5 mg/l (MV ± 1 SD). 6 von 139 individuellen Plasmaproben (4%) zeigten sich 
gegenüber einer durch Gentamicin ausgelösten Thrombingenerierung resistent. Bei 
3 von 139 individuellen Plasmaproben (2%) zeigte Gentamicin einen inhibitorischen 
Effekt auf die Thrombingenerierung und zwar mit approximativ 50% inhibitorischen 
Konzentrationen (approx. IC50) von ca. 1-2 mg/l.  
Gentamicin aktiviert also die intrinsische Gerinnung mit großen inter-individuellen 
Unterschieden. Ein hämostaseologisches Monitoring und eine Testung der 
individuellen Empfindlichkeit der Gerinnung auf Gentamicin erscheinen unter einer 
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Therapie mit Gentamicin, insbesondere in einer koagulatorisch kritischen Situation, 
wie einer septischen Erkrankung, sinnvoll. 
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1.2. English Abstract 
The present work examines how human coagulation is influenced by gentamicin 
(gentamicin⋅H2SO4), an often used aminoglycoside antibiotic in clinical practice. As a 
potent broad-spectrum antibiotic, gentamicin is frequently used in life-threatening, 
septic conditions, in which physiologic human coagulation is already affected in terms 
of an increased tendency to a pathologic disseminated intravascular coagulation. The 
influence of gentamicin on the generation of thrombin, the most important enzyme of 
human coagulation, was analysed. 50 µl samples of N=139 unfrozen individual normal 
platelet poor citrated plasmas and of N=11 unfrozen normal citrated plasma pools 
were supplemented with the clinically relevant concentration of 0 to 19.6 mg/l of 
gentamicin on microtiter plates. Instantly afterwards, the RECA (recalcified coagulation 
activity assay) was performed. The important approximate 200% stimulatory 
concentrations (approx. SC200) of gentamicin on thrombin generation were 
determined in the clinically relevant ascending part of the coagulation reaction time 
vs. thrombin generation curve. 5 normal plasmas supplemented with gentamicin as 
well as with 0 IU/ml or 0.5 IU/ml of the low molecular weight heparin enoxaparin-
natrium were also analysed. 130 of 139 (94%) of the individual normal plasmas 
triggered thrombin generation with an approx. SC200 of 2.0 ± 2.5 mg/l (MV ± 1SD). 
Of the N=139 individual normal plasmas that were supplemented with up to 20 mg/l of 
gentamicin, 6 of 139 (4%) were resistant towards gentamicin-triggered thrombin 
generation. 3 of 139 (2 %) plasmas did not have an approx. 200% stimulatory 
concentration, but had an approx. 50% inhibitory concentration of 1-2.5 mg/l of 
gentamicin. 
Gentamicin⋅H2SO4 triggers intrinsic coagulation and thus thrombin generation with 
great inter-individual differences. A hemostatic monitoring and testing of the 
individual sensibility to gentamicin is reasonable, especially in a critical pro-coagulant 
situation like sepsis.  
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2. Introduction 
2.1. The human hemostasis 
Hemostasis is the system of generation and destruction of thrombi. Didactically, 
human hemostasis is divided in 3 parts[90]: 
1. Primary hemostasis 
2. Secondary hemostasis 
3. Tertiary hemostasis 
Primary hemostasis is the system of the thrombocytes, secondary hemostasis is 
constituted of plasmatic coagulation and tertiary hemostasis represents fibrinolysis. 
This didactical classification does not exactly reflect the biologic processes, but it is 
chosen due to a simplified representation. 
Pathophysiologically or clinically, secondary hemostasis is often the most important 
part of hemostasis, because many diseases via cell fragments directly start with 
activation of secondary hemostasis with its protease cascades, autocatalytic 
amplifications, and phospholipid-enhancements[70].  
Physiologically, hemostasis often starts with activation of primary hemostasis. A break 
in the vasculature exposes extracellular matrix (collagen molecules) to flowing blood 
and initiates the coagulation process. Platelets adhere to the site of injury through a 
number of specific interactions[42] mainly through collagen of the basement 
membrane and associated adhesive proteins[69]. Von Willebrand Factor (vWF) binds 
exposed collagen and, after a conformational change, binds platelets through the 
platelet receptor glycoprotein-(GP-)Ib-IX-V complex[42] and activates primary 
hemostasis[16]. 
After adhesion platelets undergo cytoskeletal changes and become stellated by 
developing pseudopodia in order to cross-link. Moreover, they release calcium ions, 
ADP, serotonin, and thromboxan A2 from their granula[86]. Thromboxan A2 has 
vasoconstrictive properties[93]: it reduces the blood flow rate and stops the bleeding. 
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The first clot develops; the cross-link of platelets leads to a primary wound closure and 
thrombin is generated. 
The result of human plasmatic hemostasis is the formation of fibrin generated by 
thrombin during the three phases of plasmatic coagulation: initiation, amplification, 
and propagation[101]. Fibrin is stabilized via gamma-gamma dimerization (cross-
linking) of its D-subunits by factor 13a. 
Plasmatic hemostasis is divided in an extrinsic and in an intrinsic pathway. 
The extrinsic pathway is also called tissue factor pathway, because the injured cell 
(often monocytes or fibroblasts) releases tissue factor (TF), which activates coagulation 
factor 7 to factor 7a. F7a-TF-PL-Ca2+, the extrinsic ten-ase, activates factor 10; 
factor 10a converts prothrombin (factor 2) into its active form, thrombin (factor 2a). 
The intrinsic pathway is also called contact activation pathway, because a changed 
surface folds factor 12 to factor 12a (F12a) or pre-kallikrein (PK) to kallikrein (K). Factor 
12a and kallikrein generate each other; F12a activating pre-kallikrein and kallikrein 
activating Factor 12. Factor 12a and kallikrein activate factor 11. Factor 11a activates 
factor 9 to factor 9a (F9a); then F9a-F8a-PL-Ca2+, the intrinsic ten-ase, activates factor 
10 to factor 10a[55]. 
In the final common pathway factor 10a in complex with F5a-PL-Ca2+ converts 
prothrombin into thrombin. Thrombin converts fibrinogen into fibrin. Factor 13a is 
generated by thrombin and cross-links a D-gamma chain to another D-gamma chain, 
stabilizing the fibrin clot. 
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Figure 1 
Conversion of fibrinogen into fibrin by thrombin. Reproduced with permission of PLoS 
One[7]  ( =0.7 µm).  
Panel A. Conversion of fibrinogen into fibrin. The fibrinogen molecule is composed of 
three pairs of polypeptide chains. Thrombin splits the fibrinopeptides A (FpA) and B 
(FpB) from the central domain E. Domain D and E interact leading to aggregation of 
protofibrils; fibrin is generated.  
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Panel B. Schematic representation of thrombin converting fibrinogen into fibrin. Cross-
linking of fibrin is induced by factor 13a which is activated by thrombin. 
Panel C. Multiphoton images of fibrin. Fibrin fibers (i), fiber branch junctions(ii), 
crossing fibers (iii) and fibrin clusters (iv)[7]. 
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2.2. The protease thrombin 
Thrombin is the most important enzyme of human coagulation[81]. Thrombin is 
synthesised as prothrombin in the liver. It is a serine protease and it is generated from 
its inactive precursor prothrombin upon intrinsic or extrinsic coagulation 
activation[85]. Prothrombin binds together with calcium ions to the negatively charged 
phospholipid membranes. It also binds to the macromolecular enzyme complex 
prothrombinase (factor 10a, 5a, Ca2+, and phospholipids). This converts prothrombin 
into the active enzyme thrombin[11]. Thrombin activation in vivo is a very complex 
procedure. The activation reactions are divided in three phases: initiation, activation, 
and propagation phase[15]. In the activation phase, a matrix change of blood 
generates Factor 12a and kallikrein or active tissue factor binds factor 7. The resulting 
complexes (the intrinsic ten-ase F9a-F8a-PL-Ca2+ or the extrinsic ten-ase 
F7a-F5a-PL-Ca2+) activate factor 10. The amplification phase is characterised by factor 
10a or kallikrein converting small amounts of prothrombin to thrombin which activates 
cofactors 8, 5, and platelets. 
 The most important hemostatic function of thrombin is to convert fibrinogen into 
fibrin[85]. On this way thrombin is the main enzyme of plasmatic hemostasis. Because 
of factor 5 and 8 activation during the amplification phase, thrombin indirectly 
catalyses its own generation in terms of a positive feedback mechanism[68]. Factor 5 
and 8 are therefore very important for thrombin generation[10]. Active thrombin is 
composed of two polypeptide chains connected through a disulfide bond. Polypeptide 
chain A consists of 36 amino acids and polypeptide chain B of 259[59].  Recent studies 
demonstrated how thrombin concentration biochemically influences the growing 
thrombus in vivo, determining fiber thickness, density, structure, rate of formation and 
stability of the fibrin clot[101]. Abnormal thrombin activities and a consequential 
abnormal fibrin clot increases the risk of insufficient fibrinolysis[17].  
 
Thrombin in a side reaction can also bind to thrombomodulin. The 
thrombin/thrombomodulin complex activates protein C. Activated protein C destroys 
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coagulation factors 5a and 8a. Therefore thrombomodulin can shift the activity of 
thrombin towards anticoagulation. Based on the membrane binding and activation 
steps, thrombin should only be released into the local region of injury and bleeding. 
However, in pathophysiology high activities of thrombin often gain access to the 
systemic circulation causing a change from normal to pathologic intravascular 
coagulation (NIC  PIC). 
 
The enzyme activity of thrombin is controlled by different inhibitors, especially by the 
serpin antithrombin-3 (AT-3), which is the major inactivator of thrombin in human 
blood. Additionally, the serpin heparin cofactor 2 is a minor inactivator of thrombin. 
The broad spectrum inhibitor alpha2-macroglobulin constantly complexes about 10% 
of thrombin generated in blood, the complexed thrombin is still amidolytically active; it 
is rather transported than inactivated. The serpins binding is enhanced by 
polysulphated glycosaminoglycans such as heparin. Hirudin, a polypeptide coagulation 
inhibitor produced by the leech, inhibits thrombin by interaction with its active 
centre[59]. Fibrin can also inhibit thrombin: thrombin gets entrapped in generated 
fibrin (antithrombin-1 = AT-1)[58]. 
 
Thrombin also has an effect on different cell types not directly related to hemostasis, 
but to inflammation, proliferation, or reparative response to wounding[85]. On this 
way thrombin is an important inflammatory mediator. It is reported for thrombin to 
enhance T lymphocyte and monocyte activation and induce the release of 
proinflammatory cytokines such as interleukin 6 and interleukin 8. Furthermore, 
thrombin inhibits the release and the expression of IL-12 in human peripheral blood 
mononuclear cells. Such inhibition is accompanied by enhancement of IL-10 release. 
This mechanism could be responsible for increased complications in 
immunosuppressed patients after an injury[62]. Furthermore, thrombin seems to be a 
stimulus for fibrogenic cell activation, so that thrombin antagonism is thought to 
improve e.g.  progredience of liver fibrosis[25]. 
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2.3. Innovative Thrombin Generation Tests[89] 
In vivo Thrombin Activity (Sytemic 2a Activity- F2a Test) 
Currently the best bio-marker for the in vivo thrombin generation is the test for 
amidolytic thrombin activity in plasma[87, 89, 90]. Thrombin entrapped in the 
α2-macroglobulin cage is chromogenically determined via fast amidolysis of a 
tri amino acids-paranitroanilide (pNA) substrate. EDTA blood is taken and centrifuged 
within 1-2 h at 23°C and the resulting plasma is stabilized 1+1 with 2.5 M arginine at a 
pH of 8.6. In the assay 1 part of arginine-stabilized EDTA plasma can be incubated with 
1 part of 0.77 mM chromogenic thrombin substrate HD-CHG-Ala-Arg-pNA in 
1.25 M arginine, at a pH of 8.7 and the specific increase in absorbance (∆A) at 405 nm 
with time at 37°C is determined. 
 
In vitro Thrombin Activity 
Thrombin activity determinations in plasma are extremely difficult, because ongoing 
plasmatic coagulation and the constant generation of other proteases such as 
kallikrein or fibrin (= AT-1) falsifies photometric measurements. To avoid this, the 
amino acid arginine is added in supra-1 molar final concentrations, which on the one 
side immediately stops hemostasis activation, because it competitively inhibits the 
active proteolytic center of the serine proteases of coagulation, and on the other side 
depolymerizes uncrosslinked fibrin. Based on these two properties of arginine, three 
ultra-specific and ultra-sensitive tests have been developed, the extrinsic coagulation 
activity assay (EXCA), the intrinsic coagulation activity assay (INCA), and the recalcified 
coagulation activity assay (RECA). All of these three new methods have in common 
that hemostasis activation is stopped by arginine after a certain coagulation reaction 
time (CRT). The chromogenic substrate is added after three minutes and the ∆A is 
determined. The results can be expressed in mIU (milli-international units) thrombin 
generated or in thrombin generation in percentage of the mean value of normal 
donors. 
18 
Extrinsic Coagulation Activity Assay (EXCA) 
EXCA is used to measure extrinsic coagulation. 5 µl of 1 ng/ml tissue factor and 
250 mM of CaCl2 is added to 50 µl of plasma to activate extrinsic coagulation. After 
1 min (main value) or 2 min (control value) coagulation reaction time at 37°C, 100 µl 
arginine-stop-reagent is added and 25 µl of 1 mM chromogenic thrombin substrate-
reagent is added after 3 min. Thrombin generation is measured through photometric 
extinction by microtiter plate photometers with a 1 mA resolution. Plasmatic 
anticoagulants which influence the extrinsic or common phase of coagulation can be 
monitored through EXCA very accurately. 
 
Intrinsic Coagulation Activity Assay (INCA) 
INCA is used to measure intrinsic coagulation. 5 µl of 250 mM CaCl2 and 5 µl of SiO2 is 
added to 50 µl citrated plasma to start the coagulation reaction. After 4 min 
(main value) or 5 min (control value) coagulation reaction time (CRT) at 37°C, 
100 µl arginine-stop-reagent is given to stop coagulation. After 3 min incubation to 
depolymerize uncrosslinked fibrin, 25 µl of 1 mM chromogenic thrombin 
substrate-reagent is added. Thrombin generation is measured through photometric 
extinction. Plasmatic anticoagulants which influence intrinsic or common phase of 
coagulation can be monitored through INCA very accurately. 
 
Recalcified Coagulation Activity Assay (RECA) 
RECA is basically an ultra-sensitive INCA. 5 µl of 250 mM CaCl2 is added to 50 µl of 
citrated plasma in pure-grade polystyrene microwells to initiate coagulation. Usually, 
after 20 min (main value) or 30 min (control value) at 37°C, 100 µl  of arginine-stop 
reagent is added. 
 After 3 min 25 µl of 1 mM chromogenic thrombin substrate-reagent is added. 
Thrombin generation is measured through photometric extinction. Particularly, RECA 
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can be used very well to study slightest prothrombotic tendencies of plasma or 
changes of the plasma matrix (e.g. by drugs) in individual patients, which is its main 
indication. 
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2.4. The Aminoglycoside Gentamicin 
Gentamicin is a very important aminoglycoside antibiotic[13, 34, 65]. It is produced by 
various species of the gram-positive bacterial genus Micromonospora by 
fermentation[45, 46, 92] as a mixture of five major related components referred to as 
gentamicin C1, C1a, C2, C2a, and C2b[77]. The C2-derivatives are the main type. 
 
 R1 R2 R3  Proportion 
 
C1 –CH3 –H –CH3  20−40 % 
C1a –H –H –H  10−30 % 
C2 –CH3 –H –H  
C2a –H –CH3 –H  
C2b –H –H –CH3  
40−60 % 
 
Figure 2 
Chemical structure of gentamicin[26] 
Pure gentamicin (MW= 477.6 Daltons) consists of two amino sugar groups (to the left 
and to the right) and one aminociclitol group (in the middle), as illustrated in figure 2. 
The drug usually also contains H2SO4[26, 52]. It is mostly used to treat bacterial 
infections caused by gram-negative bacteria such as Escherichia coli, Salmonella spp., 
Shigella spp., Enterobacter spp., Citrobacter spp., Acinetobacter spp., Proteus spp., 
Klebsiella spp., Serratia spp.,Morganella spp., Pseudomonas spp., and by some gram-
positive bacteria like Staphylococcus aureus and some streptococci[94]. About 50% of 
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gram positive staphylococci are sensible to gentamicin. The drug is not effective against 
Bacteroides spp., Streptococcus pneumoniae, Burkholderia cepacia, and 
Strenotrophomonas maltophilia[94]. Gentamicin is not used in the treatment of 
bacterial infections caused by Neisseria gonorrhoe, Neisseria meningitides, and 
Legionella pneumophila because of a feared shock reaction due to the release of 
lipopolysaccharides acting as pyrogenic endotoxins. 
Gentamicin binds the bacterial 30S-ribosomal subunit and thus causes misreading in 
bacterial protein synthesis. That is why, gentamicin has no bacteriostatic, but 
bactericidal properties. The antibacterial effect is concentration dependent[2]. 
Gentamicin is given either intramuscularly, intravenously, or topically. Given orally the 
relatively large molecule is insufficiently absorbed from the small intestine because of 
its lipophobic properties[100]. Gentamicin almost does not bind to plasma proteins 
and does not undergo metabolisation. Gentamicin is eliminated by the kidneys with a 
half-life of 1.5 - 2 hours. Renal insufficiency results in a slower elimination of 
gentamicin and thus has an increased risk for accumulation and toxic side-effects. It is 
therefore important to adapt gentamicin dosage in case of renal insufficiency[2].  
 
During prolonged treatments gentamicin can act as a vestibulotoxin[9, 78]. 
Approximately 5% of patients on gentamicin experience vestibular ototoxicity[74]. 
There seems to be a genetic predisposition to gentamicin induced vestibular 
dysfunction[74]; however, genetic tests are not always recommended because of the 
application of the drug in severe cases and critical ill patients, in which waiting for the 
gene analysis results could negatively influence the patient outcome[75]. Although the 
precise mechanisms are not still completely known, there is the supposition that 
gentamicin penetrates into the endolymphatic fluid of the scala media, permeates 
non-selective cation channels on the apical surface of hair cells, generates toxic 
reactive oxygen species, and furthermore interferes with other cellular pathways[48]. 
In detail, aminoglycosides were found to be able to block the transduction channels at 
the tips of stereocilia and the N-type and P/Q type channels in neurons as well as 
acetylcholine-evoked K+ currents in outer hair cells. Some antioxidants such as 
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glutathione or other drugs such as mannitol or salicylate have been shown to protect 
against aminoglycosides ototoxicity in vivo[8].  
 
A further side effect of aminoglycosides and thus gentamicin is their nephrotoxicity, 
which occurs in 10-20% of therapies[53]. Gentamicin is up-taken in epithelial cells of 
the proximal tubulus and remains there for a while, which results in 
nephrotoxicity[60]. Nephrotoxicity, resulting in renal dysfunction, is caused by tubular 
necrosis, epithelial edema of proximal tubules, cellular desquamation, tubular fibrosis, 
glomerular congestion, perivascular edema, and inflammation[6]. Acidic phospholipids 
are responsible for binding gentamicin, but more recently it has been reported that 
megalin, an endocytic giant receptor, is important for binding gentamicin. So megalin 
antagonism could be a way to prevent gentamicin-induced nephrotoxicity[60]. 
Nephrotoxicity clinically manifests with slow rises in serum creatinine and marked 
decreases in glomerular filtration rate[53]. 
 
In order to reduce side effects of a gentamicin treatment, the maximal levels should be 
less than 20 mg/l[39, 63]. Typical minimal plasma levels of free gentamicin are around 
5 mg/l, typical maximal plasma levels are around 10 mg/l. 
 
Currently there are some studies about gentamicin dosing; whether once-daily giving is 
more effective than several times giving and which plasma level should be reached in 
different bacterial infections. These studies mostly concern pediatric gentamicin 
dosing[27, 31, 37, 39, 43, 100]. The reason for these studies is the so called first 
exposure effect; if the bacterial cell survives the first exposure to gentamicin, a 
subsequent second exposure will not be effective as the first. This is the reason why, 
gentamicin is more effective given once in a high dosage than given several times in 
small doses[2]. 
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2.5. The disseminated intravascular coagulation 
Pathologic disseminated intravascular coagulation (PIC) is a very complex and 
dangerous condition[1, 5, 33, 35, 37, 38, 49, 64, 67, 96, 97]. It is caused by enhanced 
systemic intravascular coagulation activation on the bottom of various underlying 
conditions[47] like shock, intravascular haemolysis, release of tissue factor, bacterial 
endotoxins, proteolytic enzymes, particulate, or colloidal matter anoxia and 
anoxaemia, endothelial damage and ingestion of certain lipid substances[54]. This is 
followed by massive systemic generation of thrombin. Low levels of antithrombin 
(AT-3) insufficiently inhibit coagulation activation[30]. The result is circulating micro-
thrombi, ischemia, and organ failure. Seldomly, massive consumption coagulopathy, 
so-called overt DIC, can occur with massive bleeding plus intravasal fibrin clotting. 
Early diagnosis and early treatment are essential for the outcome of the patient. 
Systemic thrombin activity is an important biomarker in the phase of pre-PIC[90] and 
antithrombin, fibrinogen, platelets, and prothrombin time seem to be important 
hemostatic markers for the begin of the overt DIC phase[99]. 
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2.6. Background of the work 
Coagulation activation and thus activation of thrombin play a very important role in 
clinical daily work. There are many diseases or deaths caused by systemic or local 
micro- or macro-thrombi, pathological activations of the coagulation system. 
In such situations it would be important to know if drugs could additionally trigger the 
patient coagulation system and aggravate his condition. Some drugs are known 
triggers for pathological coagulation activation (e.g. asparaginase) and there is the 
suspicion that the important aminoglycoside gentamicin can trigger coagulation 
activation, too. Because gentamicin is often used in treatment of sepsis and sepsis is a 
possible cause of pathologic disseminated intravascular coagulation, it would be 
important to know if gentamicin itself could further aggravate the already affected 
coagulation of these patients. The question is: 
Does gentamicin influence plasmatic thrombin generation? 
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3. Plasma, Materials and Methods 
3.1. Materials 
3.1.1. Equipment 
 
Mikrotiter plate photometer 
Milenia; DPC, Los Angeles, USA 
 
Digitally controlled water – bath (37°C) 
Memmert; Büchenbach, Germany 
 
Sterile 37°C incubator 
Melag; Berlin, Germany 
 
3.1.2. Material 
 
Polypropylene monovettes containing 0.5 ml 106 mM sodium citrate 
Sarstedt; Nümbrecht, Germany 
 
Polystyrene U-wells (highest quality) 
Brand; Wertheim, Germany; article nr. 701300 
 
Multipette 
Eppendorf; Hamburg, Germany 
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3.1.3. Chemicals 
 
Gentamicin 
Gentamicin-ratiopharm40SF, Ulm, Germany;  
The drug vial contained 1 ml 67.8 mg gentamicin ⋅ H2SO4 = 40 mg gentamicin;  
1 mg gentamicin sulphate = 590 µg gentamicin. 
 
Enoxaparin  
Clexane; Aventis; Frankfurt, Germany 
 
CaCl2 ,
 
arginine, Triton X 100 
Sigma; Deisenhofen, Germany 
 
Siliconized 20 ml glass vials 
Siemens-DadeBehring; Marburg, Germany; article nr. OVKE49 
 
Chromogenic thrombin substrate 
HD-CHG-Ala-Arg-pNA 
Pentapharm; Basel, Switzerland; 100 mg article nr. 081-03 
 
Purified bovine thrombin (130 IU/vial) 
Siemens-DadeBehring 
 
Human albumin 
CSL Behring; Marburg, Germany 
 
 
0.9% NaCl 
Braun Melsungen, Germany 
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3.1.4. Plasma samples 
 
 This study has been approved by the local ethic commission of the university hospital 
of Marburg (181/09). N=139 unfrozen individual normal platelet poor citrated plasma 
from healthy volunteers who gave written informed consent and N=11 pools of 
unfrozen normal plasma, consisting of 5-20 individual samples, were analysed. The 
blood samples derived from voluntary students either from the laboratory or during 
the practical course of Clinical Chemistry. Before drawing blood and after written 
consent, the donors were asked if they had a coagulation disease or if they were on 
anticoagulation treatment. The study was performed only with normal samples. 
Normal plasma was considered as fresh, if the time between withdrawal and test was 
less than or equal to 2h. More than 2h to 6h old plasma was considered as normal. The 
citrated blood was centrifuged at 2800 g and 23°C for 10 minutes. The cell poor plasma 
was used for the study. 
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3.2. Methods 
3.2.1. The recalcified coagulation activity assay (RECA) 
50 µl of individual normal platelet poor citrated plasma (0.5-6 h 23°C old) and pooled 
normal plasma, consisting of 5-20 individual samples, was supplemented with 
0-19.6 mg/l (final plasma concentration) gentamicin by immediate repetitive 1+1 
dilution in high-quality polystyrene U-wells microtiter plates. Additionally, 5 samples of 
individual unfrozen normal plasma were added 50 µl of gentamicin⋅ H2SO4  as well as 
0 IU/ml or 0.5 IU/ml of enoxaparin-natrium by an Eppendorf-multipette® in order to 
analyse the prophylactic action of this low molecular weight heparin on gentamicin 
induced thrombin generation. Because of its ultra-specificity and ultra-sensitivity to 
detect slightest prothrombotic tendencies of plasma, the recalcified coagulation 
activity assay (RECA) was performed immediately thereafter. 
RECA can be sub-divided in two phases: firstly the thrombin generation phase and 
secondly the thrombin detection phase. 
 
1. Thrombin generation phase 
In the first phase 5 µl of RECA-trigger is added in duplicate by an 
Eppendorf-multipette® with 0.9% NaCl-rinsed in new disposable polypropylene-tips 
and the plates are shaken strongly for five seconds. The RECA-trigger consists of 
250 mM of CaCl2 out of 4 ml frozen/thawed aliquots in siliconized glass. After 
performing coagulation reaction times of 0-30 minutes at a temperature of 37°C, the 
coagulation reaction is stopped by 100 µl of arginine-stop-reagent. Concerning the 
samples with a coagulation reaction time of 0 minutes, the arginine-stop reagent is 
added previous to the RECA trigger. 
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2. Thrombin detection phase 
In the second phase the plasmatic turbidity is measured with a microtiter plate 
photometer with a 1 mA resolution at 405 nm at room temperature of 23°C after 
3 minutes. For this purpose 25 µl aliquoted frozen/thawed 1 mM chromogenic 
thrombin substrate HD-CHG-Ala-Arg-pNA is added in 1.25 M of arginine (CS) with a 
pH of 8.7. Afterwards the extinction ∆A405nm/t is measured at a temperature of 37°C. 
 
The RECA was standardised with 0.1 IU/ml of purified bovine thrombin in 
6 % human albumin. This substituted the plasma sample and produced a specific 
extinction ∆A405nm/t of about 3 mA/min at a temperature of 37°C. The maximal 
extinction ∆A405nm (complete cleavage of the chromogenic substrate) was about 
1000 mA; 40 % of maximum = 400 mA (= upper limit of linear range). The thrombin 
generation was designated as the thrombin activity generated during the coagulation 
reaction time minus the basal plasmatic thrombin activity at 0 minutes coagulation 
reaction time (basal F2a in normal citrated plasma = 8±2 mIU/ml; MV±1SD). The 
approximate 200 % stimulatory concentration was determined in the ascending part of 
the time vs. thrombin generation curve. Only thrombin activities being in the 
ascending part of the curve (the ratio between F2a activity at time point 1 divided by 
F2a activity at time point 2 has to be less than 1) are of relevance, because there is 
nearly no generated nascent fibrin (= antithrombin-1) that can entrap thrombin and 
inhibit its further generation. 
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4. Results 
4.1. Thrombin generation by gentamicin in individual fresh normal 
plasma 
4.1.1. Thrombin generation by gentamicin in 18 individual fresh normal plasmas 
After written consent, 18 blood samples deriving from healthy voluntary students 
were drawn and shortly afterwards centrifuged. 50 µl from every platelet-poor plasma 
was pipetted with a gentamicin concentration of 0-19.6 mg/l by repetitive 1+1 dilution 
in polystyrene u-wells microtiter plates. Afterwards RECA was performed with 5, 10, 
15, 20, 25, and 30 minutes coagulation reaction time and RECA-20 was found out to be 
the incubation time, during which thrombin is typically generated.  
Because fresh plasma is the most significant, the results of these 18 plasma samples 
are very relevant for the question if gentamicin can trigger thrombin generation. These 
18 samples were measured about 30 minutes after being drawn. Plasma samples kept 
for hours before being analysed may be pre-activated and have a higher basal activity 
of activated clotting factors generated by surface contact activation in blood tubes 
during in vitro time [98].  
The figures 4a-c illustrate the thrombin generation of these 18 samples after 
20 minutes coagulation reaction time. The 18 thrombin generation curves are 
illustrated in 3 figures respectively with 6 curves for a better overview. The tested 
plasmas are continuously labelled with N1, N2, N3, NX; N standing for normal plasma.  
The thrombin activity range between 0.01-0.1 IU/ml is the most significant, because 
there is enough generated thrombin and the generated thrombin activity is not too 
high. Too high activities would produce significant amounts of fibrin, which, as 
antithrombin-1, would absorb thrombin and interfere with its activity [57] and by this 
cause artefacts in thrombin measurements. These artefacts would be graphically 
represented as sudden drops of the thrombin generation curve after the relevant 
ascending part.  Therefore the x-axis with the gentamicin concentration stops in 
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certain graphs at values smaller than 19.6 mg/l. This was done for a clearer 
presentation of the ascending part of the thrombin generation curve and because the 
relevant question of the present work is, which gentamicin concentration is needed to 
generate twofold thrombin and thus the approximate 200% stimulatory concentration, 
which can be read in the early ascending part of the graph in most cases. The y-axis 
varies respectively to the generated thrombin activity. According to results there are 
strong responders that react to a very low or low dosage of gentamicin between 
0.1-2.5 mg/l with twofold enhanced thrombin generation, moderate responders, with 
twofold increased thrombin generation at gentamicin concentrations between 
2.5-6 mg/l, low responders that react to a medium or high dosage of gentamicin 
between 6-19.6 mg/l with twofold enhanced thrombin generation, and resistant 
responders, whose thrombin generation is not influenced by gentamicin 
concentrations of smaller than or equal to 19.6 mg/l. 
 
RESPONDER APPROX. 200% GENTAMICIN 
STIMULATORY CONCENTRATION in mg/l 
Strong responder 0.1-2.5 
Moderate responder 2.5-6 
Low responder 6 -19.6 
Resistant responder >19.6 
 
Figure 3 
Classification criteria for the approx. 200% stimulatory concentrations of the 
responders
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Figure 4a  
Thrombin generation in the individual fresh normal plasmas N1-N6 expressed in 
IU/ml 
 
Figure 4a illustrates the thrombin generation in 6 of 18 fresh normal plasmas after 
gentamicin supplementation. The normal plasmas N1-N6 are examples for very strong 
responders to gentamicin addition. They already react to very low triggering 
gentamicin dosages of smaller than 0.5 mg/l with twofold enhanced thrombin 
generation, as illustrated in the ascending part of their curves. Plasma N6 even doubles 
its thrombin generation at a very low gentamicin concentration of 0.2 mg/l gentamicin. 
Its graph is steep from the beginning; it has a basal thrombin activity of 0.01 IU/m and 
reacts to 0.2 mg/l of gentamicin with a thrombin activity of 0.02 IU/ml, as shown in the 
N6 graph. These results are very representative and relevant, because they 
demonstrate the gentamicin ability of triggering thrombin generation and they show 
that very low approximate 200% stimulatory concentrations can already trigger 
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thrombin generation. Additionally, the analysed plasmas were fresh (about 0.5 h at 
room temperature) and thus of high significance. 
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Figure 4b 
Thrombin generation in the individual fresh normal plasmas N7-N12 expressed in 
IU/ml 
 
Figure 4b illustrates the thrombin generation in 6 of 18 fresh normal plasmas after 
gentamicin supplementation. The normal plasmas N7-N12 are also strong responders 
to gentamicin addition, reacting to gentamicin dosages between 0.3-1 mg/l with 
twofold increased thrombin generation. N10 is the strongest responder. Its curve 
starts at a basal thrombin activity of 0.01 IU/ml and reaches a thrombin activity of 
0.02 IU/ml at a gentamicin concentration of 0.2 mg/l. 
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Figure 4c 
Thrombin generation in the individual fresh normal plasmas N13-N18 expressed in 
IU/ml 
 
Figure 4c illustrates the thrombin generation in 6 of 18 fresh normal plasmas after 
gentamicin supplementation. The normal plasmas N13, N14 and N18 can be 
interpreted as strong responders; their triggering dosage is between 1-2 mg/l of 
gentamicin. The normal plasma N15 is a low responder reacting to a dosage of 10 mg/l 
of gentamicin with twofold thrombin generation, whereas N16 is a moderate 
responder with an approx. 200% stimulatory concentration of 5 mg/l of gentamicin. 
The normal plasma N17 is an example for a resistant responder. Its thrombin 
generation is not influenced by gentamicin concentrations up to 19.6 mg/l. 
15 plasmas out of these 18 samples of fresh normal plasma are strong responders. 
Their thrombin generation is doubled by gentamicin dosages between 0.2-2 mg/l. 
One plasma is a moderate responder. Its thrombin generation is twofold increased by 
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a gentamicin dosage of 5 mg/l. One plasma is a low responder with an approx. 200% 
stimulatory concentration of 10 mg/l of gentamicin. One plasma is found to be 
resistant. The following table shows the approx. 200% stimulatory concentrations of 
these 18 samples sorted by test persons. The mean value for the 200% approx. 
stimulatory concentration is 1.4 mg/l of gentamicin, the standard deviation is 2.5. 
 
Normal Approx. 
Plasma SC200 [mg/l] 
N1 0.35 
N2 0.25 
N3 0.5 
N4 0.35 
N5 0.3 
N6 0.2 
N7 0.3 
N8 0.6 
N9 0.3 
N10 0.2 
N11 1 
N12 1 
N13 2 
N14 1 
N15 10 
N16 5 
N17 resistant 
N18 1 
MV* 1.4 
SD* 2.5 
*Resistant responders are not considered 
Figure 5 
Approx. 200% stimulatory concentrations of 18 individual fresh normal plasmas 
 
A pool was mixed out of these 18 individual fresh normal plasmas and 50 µl of it was 
pipetted in polystyrene u-wells microtiter plates and supplemented with 0-19.6 mg/l of 
gentamicin by repetitive 1+1 dilution. Afterwards, RECA with 5, 10, 15, 20, 25, and 
30 minutes coagulation reaction time was performed with the observation of pooled 
36 
fresh normal plasma needing a shorter coagulation reaction time than individual 
plasma probably because of the ability for one susceptible plasma to trigger the whole 
pool. After being activated, the susceptible plasma activates the other plasmas, leading 
to a significant thrombin generation. This is probably also the reason for the approx. 
200% stimulatory concentrations of pooled plasma being lower compared to individual 
plasma. The pooled plasma of these 18 samples shows a significant thrombin 
generation at a coagulation reaction time of 15 minutes. Pools are continuously 
designated with P1, P2, etc. The following figure illustrates pool P1 mixed out of the 
18 samples of fresh plasma.  
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Figure 6 
Thrombin generation in the pooled fresh normal plasma P1 expressed in IU/ml 
 
The red thrombin generation curve starts at a higher basal thrombin activity probably 
caused by the plasma samples activating each other. The thrombin generation is 
twofold enhanced at a gentamicin concentration of 0.8 mg/l. This approx. 200% 
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stimulatory concentration is lower than the mean value of individual measurements 
probably because one sensible plasma can activate and influence the others in their 
thrombin generation leading to twofold enhanced thrombin generation at lower 
gentamicin concentrations. 
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4.1.2. Thrombin generation by gentamicin in 14 individual fresh normal plasmas 
Other 14 blood samples of voluntary donors were drawn during their practical course 
of Clinical Chemistry after written consent. After centrifugation 50 µl of every 
individual fresh platelet-poor plasma was pipetted with a gentamicin concentration of 
0-19.6 mg/l by repetitive 1+1 dilution in polystyrene u-wells microtiter plates. 
Afterwards RECA with 5, 10, 15, 20, 25, and 30 minutes coagulation reaction time was 
performed. Once again, 20 minutes was confirmed to be the most effective incubation 
time for fresh plasma. Since the blood samples were kept only 2 h at room 
temperature before being processed, these results are also very significant. Due to a 
clearer presentation, the results are subdivided in 2 figures, figure 7a and 7b, 
respectively with 7 curves. Once again, attention must be paid on the activity range 
between 0.01-0.1 IU/ml, being the most significant range. 
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Figure 7a  
Thrombin generation in the individual fresh normal plasmas N19-N25 expressed in 
IU/ml 
 
Figure 7a illustrates the thrombin generation in 7 of 14 fresh normal plasmas after 
gentamicin supplementation. The normal plasmas N19, N21, N23, and N25 are strong 
responders to gentamicin addition. These plasmas react to the low triggering 
gentamicin dosages between 0.8-2 mg/l with a twofold enhanced thrombin 
generation, as shown in the ascending part of their curves. The normal plasmas N20 
and N24 are moderate responders. Their approx. 200% stimulatory concentrations are 
between 3.2-4 mg/l of gentamicin. The normal plasma N22 is a low responder: it 
doubles its thrombin generation at a concentration of 8 mg/l of gentamicin. 
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Figure 7b  
Thrombin generation in the individual fresh normal plasmas N26-32 expressed in 
IU/ml 
Figure 7b shows the thrombin generation in 7 of 14 fresh normal plasmas after 
gentamicin supplementation. The normal plasmas N26, N27, N29, N30, N31, and N32 
are examples for strong responders. Their approx. 200% stimulatory concentrations 
are between 0.3-2.4 mg/l of gentamicin. The strongest responder of this group is N27. 
Its thrombin generation curve starts at a basal activity of 0.01 IU/ml. It enhances 
twofold its thrombin generation at a gentamicin concentration of 0.3 mg/l, as shown at 
the second point of its curve. The plasma sample N28 can be interpreted as a 
moderate responder. Its thrombin generation curve is quite flat; its approx. 200% 
stimulatory concentration is 4.8 mg/l. 
10 out of these 14 samples of fresh normal plasma are strong responders. Their 
thrombin generation is doubled by gentamicin dosages of 0.3-2.4 mg/l. 3 plasmas are 
moderate responders. Their thrombin generation is twofold enhanced by gentamicin 
dosages between 3.2-4.8 mg/l. One plasma was a low responder; it doubles its 
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thrombin generation at a gentamicin dosage of 8 mg/l of gentamicin. The following 
table shows the approx. 200% stimulatory concentrations of these 14 samples sorted 
by test person. The mean value for the 200% approx. stimulatory concentrations is 
2.3 mg/l of gentamicin, the standard deviation is 2.1. 
 
Normal 
Plasma 
Approx. 
SC200 [mg/l] 
N19 0.8 
N20 3.2 
N21 2 
N22 8 
N23 1.6 
N24 4 
N25 1.6 
N26 0.6 
N27 0.3 
N28 4.8 
N29 2.4 
N30 1.1 
N31 1.2 
N32 1.2 
MV 2.3 
            SD 2.1 
 
Figure 8 
Approx. 200% stimulatory concentrations of 14 individual fresh normal plasmas 
The approximate 200% stimulatory concentrations of these 14 samples are slightly 
higher than the approx. 200% stimulatory concentrations of the 18 samples presented 
in chapter 4.1.1 previously. Most of the 18 samples had very low triggering gentamicin 
dosages, whereas these 14 samples show higher approx. 200% stimulatory 
concentrations. The explanation for this difference is probably the 18 samples being 
kept only 0.5 h at room temperature before examination. The probability of 
coagulation activation by self activation and contact activation with the blood tubes is 
increased by the time it takes to start with RECA. If coagulation is basically activated, 
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contact factors are consumed and more contact trigger (gentamicin) is needed to 
achieve the approx. 200% stimulatory concentration. 
The pool P2 was mixed out of these 14 individual fresh normal plasmas. 50 µl of P2 
was pipetted in polystyrene u-wells microtiter plates and supplemented with 
0-19.6 mg/l of gentamicin by repetitive 1+1 dilution. Afterwards, RECA with 5, 10, 15, 
20, 25, and 30 minutes coagulation reaction time was performed. Once again, pooled 
plasma needed a shorter coagulation reaction time than individual plasma. RECA-15 
was the best incubation time with a significant thrombin generation. The reason for 
this is e.g. a strong responder, reacting to low triggering gentamicin dosages and 
activating the other plasmas. For the same reason the approx. 200% stimulatory 
concentration of pooled plasma is lower than the calculated mean value of the approx. 
200% stimulatory concentrations of the 14 individual samples. 
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Figure 9 
Thrombin generation in the pooled fresh normal plasma P2 expressed in IU/ml 
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The thrombin generation curve starts at a basal thrombin activity of ca. 0.05 IU/ml, 
higher than in individual normal plasma, probably because the plasma samples 
activated each other. Then, the curve ascends and reaches a thrombin activity of 
0.1 IU/ml at a gentamicin concentration of 0.6 mg/l, which is the approx. 200% 
stimulatory concentration. Once again, this low value indicates the ability for 
one susceptible plasma to trigger the whole pool. Pooled plasma seems to behave 
similarly to normal plasma as far as gentamicin triggered thrombin generation is 
concerned. 
 
These 32 samples, the 18 of chapter 4.1.1 and the 14 of chapter 4.1.2, were the 
freshest and thus the most significant samples which were analysed. They were kept 
only 0.5-2 h at room temperature before examination. They answer the question if 
gentamicin can trigger thrombin generation with a clear “yes”: 25 of 32 normal 
plasmas doubled their thrombin generation at gentamicin dosages between 
0.2-2.4 mg/l. 10 of 32 plasmas even reacted to very low gentamicin dosages smaller or 
equal than 0.5 mg/l with twofold increased thrombin generation.  
 
In the next chapters it is shown how normal plasma, kept 2-6 h at room temperature, 
behaves after gentamicin supplementation. Then, some examples of plasmas are 
illustrated which do not have a stimulatory concentration, but an inhibitory 
concentration. At last, the question is answered if the pathologic thrombin generation 
can be prevented by the low molecular weight heparin enoxaparin-natrium (Clexane®). 
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4.2. Thrombin generation in individual normal plasma 
2-6 h old normal samples deriving from healthy voluntary students were analysed as 
well. Shortly after centrifugation 50 µl of every platelet-poor plasma was pipetted with 
a gentamicin concentration of 0-19.6 mg/l by repetitive 1+1 dilution in polystyrene 
u-wells microtiter plates. Afterwards RECA with 5, 10, 15, 20, 25, and 30 minutes 
coagulation reaction time was performed. Normal plasma was observed to have a 
different incubation time than fresh normal plasma. An incubation time of 10 to 
15 minutes was sufficient to generate thrombin. This is probably a consequence of the 
plasma being older and so pre-activated either through auto contact activation or 
through the contact to blood tube surface. If the selected incubation time was too 
short, the approx. SC200 resulted too high or the plasma appeared to be resistant to 
gentamicin. The decisive criterion was shown to be a sufficient basal thrombin activity. 
If there was no basal activity, the approx. 200% stimulatory concentrations could not 
be measured and the incubation time had to be extended to 15 or 20 minutes. The 
normal plasma N33, illustrated in figure 10, is an example for RECA-10 being a too 
short incubation time. The time has to be extended to 15 minutes to measure a 
significant thrombin generation. The normal plasma N34, shown in figure 11, 
illustrates the impossibility to determine the approx. 200% stimulatory concentration if 
there is no basal thrombin activity. In this case the incubation time has to be extended 
as well. 
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Figure 10 
Thrombin generation in the individual normal plasma N33 expressed in IU/ml 
Figure 10 demonstrates the thrombin generation in the normal plasma N33 after 
gentamicin supplementation. The thrombin generation curve of RECA-10 shows the 
insufficiency of 10 minutes incubation time. The curve does not develop appropriately 
and is quite flat. The incubation time has to be extended to RECA-15 in order to 
generate a more significant thrombin generation curve. As designated from RECA-15, 
the approx. 200 % stimulatory concentration is 1.2 mg/l of gentamicin. The thrombin 
generation curve of RECA-15 shows a further interesting phenomenon: after a strong 
thrombin generation (ascending part of the curve) thrombin gets entrapped in fibrin 
(=antithrombin 1). The thrombin generation is stopped; the curve suddenly drops 
(descending part of the curve). 
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Figure 11 
Thrombin generation in the individual normal plasma N34 expressed in IU/ml 
Figure 11 illustrates the thrombin generation in the normal plasma N34 after 
gentamicin supplementation. The normal plasma N34 shows no basal thrombin activity 
in the RECA-10 thrombin generation curve. There is no significant thrombin generation 
and the approx. 200% stimulatory concentration can not be estimated. After extending 
the incubation time to 15 minutes, the normal plasma N34 shows a significant 
thrombin generation. As determined from RECA-15, the approx. 200% stimulatory 
concentration is 1.2 mg/l of gentamicin. 
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4.2.1. Thrombin generation by gentamicin in 14 individual normal plasmas 
The figures beneath illustrate the thrombin generation by gentamicin in 14 individual 
normal plasmas deriving from healthy voluntary students. For a better overview the 
14 graphs of thrombin generation are represented in four figures, figure 12a, 12b, 12c 
and 12d, respectively with 3, 4, 3 and 4 curves. The normal plasmas continue to be 
designated with N35, N36 etc. After arriving at the laboratory and being centrifuged, 
50 µl of each platelet-poor plasma was pipetted with a gentamicin concentration of 
0-19.6 mg/l by repetitive 1+1 dilution in polystyrene u-wells microtiter plates. 
Afterwards RECA with 5, 10, 15, 20, 25 and 30 minutes coagulation reaction time was 
performed. The best incubation time with a significant thrombin generation was found 
to be RECA-15. Once again, the thrombin activity range between 0.01-0.1 IU/ml is the 
most significant. There is enough generated thrombin and the generated thrombin 
activity is not too high, so fibrin can not interfere with thrombin activity. 
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Figure 12a 
Thrombin generation in the individual normal plasmas N35-N37 expressed in IU/ml 
Figure 12a illustrates the thrombin generation in the normal plasmas N35-N37 after 
gentamicin supplementation. The normal plasmas N36 and N37 are very strong 
responders. They react to gentamicin addition with a twofold enhanced thrombin 
generation at gentamicin dosages of respectively 0.5 and even 0.1 mg/l, whereas the 
normal plasma N35 is a moderate responder. Its approx. 200% stimulatory 
concentration is of 4 mg/l of gentamicin. 
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Figure 12b 
Thrombin generation in the individual normal plasmas N38-N41 expressed in IU/ml 
Figure 12b shows the thrombin generation in the normal plasmas N38-N41 after 
gentamicin supplementation. The plasma sample N38 is a further example for a very 
strong responder. Its basal thrombin activity starts at 0.03 IU/ml and doubles at a 
gentamicin concentration of 0.3 mg/l. The plasma N39 can be interpreted as resistant. 
Its thrombin generation curve is constantly flat after gentamicin addition, apart from 
little non significant increases and decreases. The plasma N40 is a further very strong 
responder with an approx. 200% stimulatory concentration of 0.5 mg/l of gentamicin. 
The normal plasma N41 is a moderate responder. Its thrombin activity doubles at a 
gentamicin concentration of 4 mg/l, as shown in the ascending part of its graph. 
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Figure 12c 
Thrombin generation in the individual normal plasmas N42-N44 expressed in IU/ml 
Figure 12c represents the thrombin generation in the normal plasmas N42-N44 after 
gentamicin supplementation. N42 is a moderate responder. As illustrated in its purple 
graph, its basal thrombin activity starts at 0.01 IU/ml and is doubled at a gentamicin 
concentration of 5 mg/l. The normal plasma N43 is a very strong responder with a 
steep thrombin generation curve. Its approx. 200% stimulatory concentration is 
0.5 mg/l. The plasma N44 is a low responder: its approx. 200% stimulatory 
concentration is 10 mg/l of gentamicin. 
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Figure 12d 
Thrombin generation in the individual normal plasmas N45-N48 expressed in IU/ml 
Figure 12d illustrates the thrombin generation in the normal plasmas N45-N48 after 
gentamicin supplementation. Plasma samples N45, N46, and N47 are strong 
responders with approx. 200% stimulatory concentrations between 0.3-1.5 mg/l. 
N48 is a low responder. Its thrombin generation curve starts to ascend at a gentamicin 
concentration of 5 mg/l; at a concentration of 7 mg/l its thrombin generation is 
doubled. 
8 out of these 14 samples of normal plasma are strong responders. Their thrombin 
generation is doubled by gentamicin dosages between 0.1-1.5 mg/l. Three plasmas are 
moderate responders. Their thrombin generation is twofold enhanced by gentamicin 
concentrations of 4-5 mg/l. Two plasmas are low responders: they double their 
thrombin generation at gentamicin dosages between 7-10 mg/l. One plasma is 
resistant. The following table shows the approx. 200% stimulatory concentrations of 
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these 14 samples sorted by test person. The mean value of the approx. 200% 
stimulatory concentrations is 2.4 mg/l of gentamicin, the standard deviation is 3.1.  
 
Normal 
Plasma 
Approx. 
SC200 [mg/l] 
N35 4 
N36 0.5 
N37 0.1 
N38 0.3 
N39 resistant 
N40 0.5 
N41 4 
N42 5 
N43 0.5 
N44 10 
N45 1.5 
N46 0.7 
N47 0.3 
N48 7 
MV* 2.4 
SD* 3.1 
*Resistant reponders are not considered 
Figure 13 
Approx. 200% stimulatory concentrations of 14 individual normal plasmas 
 
The pool P3 was mixed out of these 14 individual normal plasmas and 50 µl of it was 
pipetted in polystyrene u-wells microtiter plates and supplemented with 0-19.6 mg/l of 
gentamicin by repetitive 1+1 dilution. Afterwards, RECA with 5, 10, 15, 20, 25, and 
30 minutes coagulation reaction time was performed. Interestingly, there was a 
significant thrombin generation at RECA-10 and RECA-20, RECA-20 being the better 
incubation time of the both and thus longer than in fresh plasma. Previously, the fresh 
normal pools P1 and P2 showed how pooled plasma needed a shorter incubation time 
than individual plasma. This difference is probably caused by 10 minutes being a too 
short incubation time for these 14 unfrozen samples. Possibly, some samples did not 
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have a sufficient basal thrombin activity yet or the most susceptible sample was not 
activated, so the incubation time had to be extended.  
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Figure 14 
Thrombin generation in the pooled normal plasma P3 expressed in IU/ml 
Figure 14 illustrates the thrombin generation in the pooled normal plasma P3 mixed 
out of 14 individual normal plasmas. The thrombin generation curve of 10 minutes 
incubation time starts at a basal thrombin activity of 0.01 IU/ml. It proceeds quite flat 
until coagulation is activated. Its approx. 200% stimulatory concentration is 1.1 mg/l. In 
contrast to the RECA-10 curve, the RECA-20 curve starts at a basal thrombin activity of 
0.025 IU/ml; the graph is steeper and thrombin generation is twofold enhanced at a 
gentamicin concentration of 0.3 mg/l. Because of the different approx. 
200% stimulatory concentrations of the two graphs and the quite high approx. 
200% stimulatory concentration of 1.1 mg/l in RECA-10, the RECA-20 graph with its 
approx. 200% stimulatory concentration of 0.3 mg/l is probably the relevant one. 
Previous measurements of thrombin generation in pooled plasma showed how the 
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incubation time of pooled plasma was lower than in individual plasma, like the pools 
P1 and P2 illustrated. 
 
In conclusion, normal plasma behaves similarly to fresh normal plasma as far as 
gentamicin triggered thrombin generation is concerned. Once again, gentamicin led to 
coagulation activation and thus to thrombin generation. 7 of 14 samples reacted to 
very low gentamicin dosages between 0.1-0.7 mg/l with twofold thrombin generation. 
 
 
 
 
 
 
 
 
 
 
During measurements some individual normal plasma samples did not have an approx. 
200% stimulatory concentration, but they had an inhibitory concentration. Thrombin 
generation was not enhanced by gentamicin, but initially inhibited. The following 
figures, figure 15 and figure 16, illustrate two examples of normal plasma, N49 and 
N50, with such an inhibitory concentration. 
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Figure 15 
Thrombin generation in the individual normal plasma N49 expressed in IU/ml 
Figure 15 illustrates the thrombin generation in the individual normal plasma N49 after 
gentamicin supplementation. Interestingly, the basal thrombin activity is high with 
3.7 IU/ml. After gentamicin addition there is not an enhancement in thrombin 
generation but the curve decreases. At a gentamicin concentration of 1 mg/l the 
thrombin activity decreases to 1.85 IU/ml. This value was designated as the approx. 
50% inhibitory concentration, the gentamicin concentration used to reduce the 
thrombin activity by half. The graph starts to ascend at a gentamicin concentration of 
5 mg/l, but does not overtake or even reach the initial thrombin activity of 3.7 IU/ml. 
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Figure 16 
Thrombin generation in the individual normal plasma N50 expressed in IU/ml 
Figure 16 illustrates the thrombin generation in the individual normal plasma N50 after 
gentamicin supplementation. The graph starts at a basal thrombin activity of 
0.13 IU/ml. After gentamicin addition the thrombin activity initially decreases very 
strong, after reaching the gentamicin concentration of 5 mg/l, it falls slower. The 
thrombin activity is reduced by half at a gentamicin concentration of 2.5 mg/l, which is 
the approx. 50% inhibitory concentration. 
These approx. 50% inhibitory concentrations found in 3 of 139 examined plasmas are 
more of theoretical interest. To determine if the inhibitory concentration is an 
analytical artefact or not, the coagulation assays INCA (intrinsic coagulation activity 
assay) or EXCA (extrinsic coagulation activity assay) have to be performed. They 
systematically measure intrinsic and extrinsic coagulation factors, and can prove if 
gentamicin can also inhibit or inactivate coagulation factors, and thus inhibit thrombin 
generation. 
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4.3. Prevention of gentamicin induced thrombin generation by the low 
molecular weight heparin Enoxaparin-Natrium (Clexane®) 
Because of the observed gentamicin effect on thrombin generation, we asked the 
question if a low molecular weight heparin can prevent this pathologic thrombin 
generation. For this purpose, enoxaparin-natrium (Clexane®) was chosen, because this 
low molecular weight heparin is currently the clinical standard for prophylaxis and 
therapy of thromboembolic affections.  Enoxaparin-natrium mainly inactivates factor 
10a, a very important coagulation factor of both the intrinsic and extrinsic pathway of 
coagulation and thus inhibits thrombin generation. A therapy with enoxaparin can be 
monitored by measuring the anti-factor 10a activity. Many authors see the anti-factor 
10a activity between 0.1-0.4 IU/ml as the prophylactic range, whereas the 
0.5-1.1 IU/ml activity range is used for therapeutic indications[103]. It needs to be 
considered that 0.1-0.4 IU/ml is probably a too low dosage for critical ill patients, who 
run a greater risk of thromboembolism. Critical ill patients, treated with gentamicin, 
may present hypercoagulability or have pre-activated plasmas because of the systemic 
inflammatory response to a bacterial infection. In this case, a higher prophylactic 
dosage of enoxaparin-natrium may be more appropriate. In 2013 Robinson et al. 
analysed whether 1mg/kg of enoxaparin daily was a more effective dosage for 
thromboprophylaxis in critical ill patients than the standard dosage of 20-40 mg daily. 
The study was based on the priori assumption that critical ill patients may need a 
higher anti-factor 10a activity range than 0.1-0.4 IU/ml, because of their higher risk of 
thromboembolism[73]. A dosage of 0.5 IU/ml was therefore used for prophylaxis and 
designated as the ideal dosage for prevention of gentamicin induced thrombin 
generation. The following four figures, figure 17a, 17b, 17c, and 17d, show four 
examples of individual normal plasmas, N51, N52, N53, and N54, in which the 
gentamicin induced thrombin generation is prevented by administration of 0.5 IU/ml 
enoxaparin-natrium (Clexane®). The samples were kept at room temperature for 
2-6 hours. After arriving at the laboratory and being centrifuged, 50 µl samples of 
every platelet-poor plasma was pipetted with a gentamicin concentration of 
0-19.6 mg/l by repetitive 1+1 dilution in polystyrene u-wells microtiter plates. 
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Additionally, 50 µl of every platelet-poor plasma was pipetted with a gentamicin 
concentration of 0-19.6 mg/l by repetitive 1+1 dilution and 0.5 IU/ml of enoxaparin-
natrium (Clexane®) in polystyrene u-wells microtiter plates. Then, thrombin generation 
was measured in RECA-15 for both. The graphs illustrate the gentamicin induced 
thrombin generation with and without Clexane® addition. 
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Figure 17a  
Prophylaxis of gentamicin induced thrombin generation by 0.5 IU/ml Clexane® 
Figure 17a illustrates the thrombin generation in the individual normal plasma N51 
after gentamicin supplementation (blue curve) and after gentamicin supplementation 
with additionally 0.5 IU/ml enoxaparin-natrium administration (orange curve). The 
blue curve starts at a basal thrombin activity of 0.01 IU/ml, it ascends steeply and 
constantly and doubles its thrombin generation at a gentamicin concentration of 
2 mg/l. The same plasma behaves completely different when both enoxaparin and 
gentamicin are added. The basal thrombin activity is low at 0.006 IU/ml, the thrombin 
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generation curve remains flat permanently, and there is no relevant thrombin 
generation.  
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Figure 17b  
Prophylaxis of gentamicin induced thrombin generation by 0.5 IU/ml Clexane® 
Figure 17b shows the thrombin generation in the individual normal plasma N52 after 
gentamicin supplementation (blue curve) and after gentamicin supplementation with 
additionally 0.5 IU/ml of enoxaparin-natrium administration (orange curve). The blue 
curve starts at a basal thrombin activity of 0.007 IU/ml. After gentamicin addition the 
thrombin generation curve ascends, its approx. 200% stimulatory concentration is 
2 mg/l of gentamicin. The orange curve has an initial thrombin activity of 0.003 IU/ml. 
After Clexane® and gentamicin are added to the normal plasma, there is no relevant 
thrombin generation. The plasma seems to be resistant to gentamicin.  
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Figure 17c  
Prophylaxis of gentamicin induced thrombin generation by 0.5 IU/ml Clexane® 
Figure 17c demonstrates the thrombin generation in the individual normal plasma N53 
after gentamicin supplementation (blue curve) and after gentamicin supplementation 
with additionally 0.5 IU/ml enoxaparin-natrium administration (orange curve). Once 
again, there is a clear difference between the two graphs: The blue curve of normal 
plasma N53 starts at a basal thrombin activity of 0.05 IU/ml and ascends after 
gentamicin addition. Its thrombin generation increases; at a gentamicin concentration 
of 4 mg/l its thrombin generation is twofold enhanced. If enoxaparin-natrium is given 
additionally with gentamicin to its plasma, the graph behaves completely different, as 
illustrated in the orange graph. There is only little thrombin generation and it does not 
reach values higher than 0.01 IU/ml. 
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Figure 17d  
Prophylaxis of gentamicin induced thrombin generation by 0.5 IU/ml Clexane® 
Figure 17d demonstrates the thrombin generation in the individual normal plasma N54 
after gentamicin supplementation (blue curve) and after gentamicin supplementation 
with additionally 0.5 IU/ml enoxaparin-natrium administration (orange curve). After 
gentamicin addition the normal plasma N54 behaves like a very strong responder, as 
shown in the blue graph. The curve is steep; its thrombin generation is doubled at a 
gentamicin concentration of 0.5 mg/l. The plasma appears to be resistant to 
gentamicin, when Clexane® is additionally given. There is no significant thrombin 
generation; the thrombin generation curve is constantly flat. 
Concluding, 0.5 IU/ml of enoxaparin-natrium prevented the gentamicin induced 
thrombin generation. When Clexane® was given additionally with gentamicin to the 
normal plasmas, they never had a thrombin generation of higher than 0.1 IU/ml, 
although the same plasmas reacted with an increased or strong thrombin generation 
when only gentamicin was added to their plasmas. 
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4.4. Conclusion 
The presented results showed how gentamicin triggers thrombin generation. It was 
illustrated how normal plasma reacts to gentamicin with an enhanced thrombin 
generation after 15-20 minutes of incubation time. The generated thrombin was 
measured with the recalcified coagulation activity assay and the gentamicin 
susceptibility appeared to be individually different. There were strong responders, 
moderate responders, low responders, and resistant responders. 36% (50 out of 139) 
of the analysed plasma samples showed an approx. SC200 of < 1 mg/l of gentamicin, 
12% (16 out of 139) even had an approx. SC200 of < 0.5 mg/l of gentamicin. The 
pathologic gentamicin induced thrombin generation could be prevented by 0.5 IU/ml 
of the low molecular weight heparin enoxaparin-natrium (Clexane®). The following 
figure, figure 18, shows the distribution of the approx. 200% stimulatory 
concentrations of the 139 analysed individual normal plasmas. 
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Figure 18 
Distribution of the approx. 200% stimulatory concentrations in 139 normal plasmas 
Figure 18 illustrates the distribution of the approx. 200% stimulatory concentrations of 
the 139 analysed individual normal plasmas. 77 out of 139 distribute around 
0.1-1.5 mg/l gentamicin. 
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All the approx. 200% stimulatory concentrations of the 139 analysed individual normal 
plasmas are sorted by test person and listed in the following table. The illustrated 
approx. 200 stimulatory concentrations were determined at 15-20 minutes coagulation 
reaction time. The mean value is 2, the standard deviation is 2.5. 
 
Normal Plasma Approx. 200% SC  
             N1 0.35 
N2 0.25 
N3 0.5 
N4 0.35 
N5 0.3 
N6 0.2 
N7 0.3 
N8 0.6 
N9 0.3 
N10 0.2 
N11 1 
N12 1 
N13 2 
N14 1 
N15 10 
N16 5 
N17 resistant 
N18 1 
N19 0.8 
N20 3.2 
N21 2 
N22 8 
N23 1.6 
N24 4 
N25 1.6 
N26 0.6 
N27 0.3 
N28 4.8 
N29 2.4 
N30 1.1 
N31 1.2 
N32 1.2 
N33 1.2 
N34 1.2 
N35 4 
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N36 0.5 
N37 0.1 
N38 0.3 
N39 resistant 
N40 0.5 
N41 4 
N42 5 
N43 0.5 
N44 10 
N45 1.5 
N46 0.7 
N47 0.3 
N48 7 
N49 IC50 1 
N50 IC50 2.5 
N51 2 
N52 2 
N53 4 
N54 0.5 
N55 1 
N56 1 
N57 2 
N58 2 
N59 2 
N60 1 
N61 1 
N62 1 
N63 3 
N64 0.3 
N65 1 
N66 5 
N67 1.5 
N68 1 
N69 6 
N70 1 
N71 resistant 
N72 3 
N73 0.5 
N74 2 
N75 2.5 
N76 13 
N77 1 
N78 3 
N79 3 
N80 1 
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N81 0.5 
N82 1.5 
N83 0.4 
N84 1 
N85 0.2 
N86 4 
N87 0.4 
 N88 0.2 
N89 0.2 
N90 0.4 
N91 resistant 
N92 0.6 
N93 5 
N94 2 
N95 0.3 
N96 2 
N97 2 
N98 0.7 
N99 0.6 
N100 5 
N101 0.8 
N102 0.2 
N103 2 
N104 0.7 
N105 0.2 
N106 0.3 
N107 0.6 
N108 0.3 
N109 1 
N110 1 
N111 2 
N112 5 
N113 1 
N114 1 
N115 10 
N116 0.64 
N117 0.32 
N118 0.4 
N119 0.9 
N120 1.2 
N121 0.2 
N122 2.5 
N123 0.6 
N124 4 
N125 15 
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N126 4 
N127 0.2 
N128 1 
N129 2 
N130 0.2 
N131 0.2 
N132 5 
 N133 2 
N134 resistant 
N135 5 
N136 resistant 
N137 1.5 
N138 1 
N139 IC50 2 
MV* 2 
             SD* 2.5 
*Resistant and inhibitory responders are not considered 
Figure 19   
Approx. 200% stimulatory concentrations of the 139 plasma samples 
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Figure 20 illustrate the number of strong, moderate, low, resistant, and inhibitory 
responders of the 139 analysed individual plasmas.  
 
RESPONDER N=139 
Strong responders (0.1-2.5 mg/l of 
gentamicin) 
99 
Moderate responders (2.5-6 mg/l of 
gentamicin) 
23 
Low responders (6-19.6 mg/l of 
gentamicin) 
8 
Resistant responders (>19.6 mg/l of 
gentamicin) 
6 
Inhibitory responders 3 
 
Figure 20 
Strong, moderate, low, resistant, and inhibitory responders in 139 analysed 
individual plasmas 
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Finally, figure 21 shows the distribution of strong, moderate, low, resistant, and 
inhibitory responders in the 139 analysed individual plasmas. 
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Figure 21 
Distribution of strong, moderate, low, resistant, and inhibitory responders in 139 
analysed individual plasmas 
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5. Discussion 
5.1. Effects of gentamicin on intrinsic coagulation and thrombin 
generation 
The present work demonstrates the triggering action of gentamicin on thrombin 
generation. The enhanced thrombin generation can be verified and quantified by the 
recalcified coagulation activity assay. This effect of gentamicin probably derives from 
its contact activation of factor 12, which leads to a thrombin generation over the 
intrinsic pathway of coagulation. Gentamicin folds factor 12 and/or prekallikrein into 
factor 12a and/or kallikrein. Factor 12a and/or kallikrein activate factor 11a, which 
generates factor 9a, an activator of F10a, the generator of thrombin. 
Gentamicin
F12
F12
F12a(folded)
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Figure 22 
Triggering action of gentamicin on intrinsic coagulation 
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Adapted with kind permission from[91] with thanks to Christel Müller from the 
photodepartment of the university hospital of Marburg. 
Because the therapeutic dosage of gentamicin is between 1.5 and 2 mg gentamicin/kg 
bodyweight[104], the described approx. 200% stimulatory concentrations are very low 
triggering doses. Possibly, the coagulation status of these susceptible subjects would 
switch from normal intravasal coagulation into pathological intravasal coagulation if 
treated with gentamicin in case of a bacterial infection. Thrombin activation and fibrin 
formation are key steps in the origin of disseminated intravascular coagulation within 
an infection[79].  
The intrinsic pathway of coagulation is believed to be less important and not relevant 
for the in vivo hemostasis[24, 55]. But why do patients suffer from hemophilia A or B, 
the deficiency of coagulation factor 8 or 9, have such bleeding problems, if the intrinsic 
pathway is not relevant for thrombus formation? Factor 12 deficiency does not seem 
to be associated with bleeding disorders, although its deficiency or selective blockade 
results in protection against thrombosis, suggesting that contact activation of factor 12 
is very important for thrombus formation in vivo and constitutes a new therapeutic 
approach to anticoagulation[22, 44, 71, 72]. Because existing anticoagulants like 
vitamin k antagonists are very effective as far as anticoagulation is concerned, but 
have seriously side effects, in 2013 van Montfoort et al. investigated, whether the 
selective blockade of intrinsic coagulation factors would be a superior target and 
would be associated with less bleeding risks than commonly used anticoagulants. They 
concluded that it is reasonable to practice more investigation on the blockade of the 
intrinsic pathway, because it is an appropriate and effective way of anticoagulation 
with reduced side effects, interactions and bleeding risks[95]. These aspects illustrate 
the importance of the intrinsic pathway of coagulation for hemostasis suggesting that 
factors, which can influence this system and cause hypercoagulability or bleeding 
disorders, are to be taken seriously, because this is very relevant for clinical practice.  
In 2006 James et al. described how gentamicin decreased the partial prothrombin time 
and increased the plasma levels of factor 8 and factor 9 in two patients with 
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hemophilia A and respectively hemophilia B[40]. This supports the assumption that 
gentamicin can directly activate coagulation factors and by this trigger thrombin 
generation. Probably, gentamicin can directly activate intrinsic coagulation factors as 
well as activate factor 12 through contact activation. 
Interestingly, ototoxicity, a serious and important side effect of gentamicin therapy, 
seems to be prevented by an anticoagulant therapy with aspirin[21, 80]. Sha et al. and 
Chen et al. believed it was because of the antioxidant effect of aspirin. Maybe the 
pathophysiology underlying gentamicin induced ototoxicity also includes a pathological 
intrinsic generation of blood micro-thrombi due to thrombin activation? Although 
aspirin mainly inhibits platelet aggregation and does not directly influence plasmatic 
hemostasis, the interactions between platelets and intrinsic coagulation factors enable 
an indirectly inhibition of contact activation of factor 12 and thus inhibition of 
thrombin generation by an aspirin induced platelet aggregation. 
The pathologic thrombin generation, which is triggered by gentamicin, is a possible 
explanation of why gentamicin can act similarly to an endotoxin[4, 14, 19, 28, 51]. 
Once daily gentamicin dosing (= high plasma concentration) is thought to go along with 
an increased risk for endotoxin reactions[14, 28]. Fibrin, which is generated by 
thrombin, stimulates monocytes to produce IL-1ß via integrin receptor CD11b/CD18 
and suppresses the production of IL-1 receptor antagonist, causing a systemic 
inflammatory reaction [3, 41, 50, 61, 66, 82, 83, 102]. Possible clinical symptoms are 
fever, chills, rigor, shivering, tachycardia, often with hypotension, respiratory 
symptoms, and muscle cramps[4]. 
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5.2. Effects of gentamicin on platelets and possible consequences in vivo 
Gentamicin does not only have effects on intrinsic coagulation, but also on 
thrombocytes. These effects have to be considered if the results are transferred into 
clinical practice. In 1997 Sakurai et al. reported how the aminoglycosides gentamicin 
and amikacin inhibited platelet aggregation and thus prevented 
EDTA-pseudothrombocytopenia for the first time[76]. In 2011 this finding was 
confirmed by Zhou et al. for amikacin, but not for gentamicin, although the 
mechanisms were still unknown[106].  
In 2012 Chen et al. demonstrated a further interaction between gentamicin and 
platelets. In their work they showed how gentamicin inhibited the ADP- and GPIIb/IIIa- 
induced platelet aggregation. Furthermore they described how the partial 
thromboplastin time protracted with increasing gentamicin concentrations starting at 
30 mg/l up to 910 mg/l, taking values of longer than 240 seconds, 10 times longer than 
physiologically[20]. Because the PTT measures the activity of coagulation factors 5, 8, 
9, 10, 11 and 12, it seems to be in contradiction with this present work, in which 
gentamicin triggering action on intrinsic coagulation was demonstrated. The PTT was 
not measured, but the enhanced thrombin generation would rather result in an 
abbreviated than in a prolonged PTT. On the other hand it must be considered that 
Chen et al. used platelet-rich plasma mixed to platelet-poor plasma. RECA, the 
coagulation assay utilised in the present work, works with platelet-poor plasma. So, 
the effects of gentamicin on platelets and the interactions between coagulation factors 
and platelets were not analysed or considered. These aspects should be considered for 
the translation of the results into clinical application and there are therefore some 
reflections for that purpose illustrated by three possible situations in vivo. 
The first one is: Gentamicin triggers intrinsic coagulation generating thrombin, which 
can be measured by RECA. Additionally, thrombocytes themselves also trigger 
thrombin generation, consume coagulation factors and prolong the in vitro measured 
PTT[88]. The measured protracted PTT is an in vitro artefact. The patient suffers from a 
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thrombophilic disorder like thrombus formation or pathologic intravascular 
coagulation. The inhibiting effect of gentamicin on platelet aggregation can be 
neglected, because the twofold trigger on thrombin generation is so strong that 
hypercoagulability does dominate.  
The second reflection is: Gentamicin triggers intrinsic coagulation generating 
thrombin, which can be measured by RECA. Additionally, gentamicin stops the ADP- 
and GPIIb/IIIa-induced platelet aggregation. Because primary hemostasis is stopped, 
plasmatic hemostasis can not be initiated. Maybe gentamicin activates factor 12 
directly and there is little thrombin generation, but the inhibition of platelet 
aggregation is so strong, that the anticoagulatory effect dominates. Clinically, the 
patient suffers from hemorrhagic disorders; he can have bleeding problems, its PTT is 
prolonged because plasmatic factors can not be activated due to the inhibition of 
platelet aggregation.  
The third one is: Gentamicin massively triggers intrinsic coagulation generating 
thrombin, a potent activator of thrombocytes. Hemostasis is then massively activated 
up to overt DIC with consumption of clotting factors. The patient can suffer from 
massive bleeding plus intravasal fibrin clotting. 
For the translation of the results into clinical application it also should be considered 
that the analysed blood samples derived from healthy donors with no coagulation 
disorders. Gentamicin is often used in septic patients, whose coagulation is already 
affected. They have a major risk for a disseminated intravascular coagulation and 
depending on the phase, they can suffer from hypercoagulability due to the activation 
of plasmatic coagulation and consumption of AT-3 or bleeding disorders caused by the 
consumption of plasmatic coagulation factors[105]. Because of the inflammation 
response of the organism to the bacteria and the production of acute phase proteins, 
also patients with a banal bacterial infection have already a changed coagulation 
status. Fibrinogen, an important component of human coagulation, also belongs to the 
acute-phase proteins and its increased production can cause hypercoagulability[29].  
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Keeping these reflections in mind, there are two main aspects to be considered. Firstly, 
gentamicin can behave differently in critical ill patients than in healthy patients as far 
as gentamicin induced thrombin generation is concerned. In critical ill patients the 
effect of gentamicin on hemostasis probably depends on many factors; e.g. on the 
gentamicin effects on platelets, on the pre-existing coagulation disorders caused by 
the bacterial infection, on the individual susceptibility to gentamicin, on the pre-
existing diseases, or on a pre-existing therapy with a heparin, etc. The reactions of 
those patients to gentamicin can not totally be predicted because of all the different 
influences, which can not be reproduced in an in vitro experiment. The second aspect 
regards critical ill patients or patients with a bacterial infection being hypercoagulable. 
Is it a consequence of their pathologic blood coagulation caused by the bacterial 
infection and/or by a disseminated intravascular coagulation or is it a consequence of 
the therapy with gentamicin? However, in both cases the consequence is the same. 
The patient suffers from a thrombophilic disorder and needs an adequate 
anticoagulation. 
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5.3. Conclusion 
Concluding, it can be affirmed with certainty that gentamicin can influence human 
hemostasis. This drugs effect was analysed and described by many authors. The 
present work demonstrates the triggering action of gentamicin on thrombin 
generation. Gentamicin can influence human coagulation on many ways. The in vivo 
effect is probably more complicated than imagined and depends on many factors like 
pre-existing disorders, gentamicin effects on platelets and plasmatic hemostasis, the 
interactions between them, and the coagulation changes induced by a bacterial 
infection. One possibility for the direct translation into clinical application is to analyse 
the effects of gentamicin on human coagulation under in vivo circumstances. It would 
be important to have the same conditions, although it would be not that easy. In ideal 
circumstances, the chosen patients have an infection caused by the same bacteria, 
they have the same pre-existing disorders, the same pre-treatment with heparin, the 
same age and gender, etc. But even in that case, the reaction to gentamicin is probably 
individually different. Therefore it seems more reasonable for clinical practice to 
control specific coagulation parameters of patients treated with gentamicin. The 
partial prothrombin time, the bleeding time, the international normalised ratio, and 
the thrombin generation should be monitored in every patient treated with gentamicin 
adapting the therapy to its specific condition. If there is an excessive thrombin 
generation, we could prove that this can be measured by the ultra-sensitive, ultra-
specific recalcified coagulation activity assay and be prevented by the administration 
of the low molecular weight heparin enoxaparin-natrium.  
The problem of thrombin generation assays is that currently there is not a standard 
method for the quantification of thrombin generation. There is poor standardisation 
and a great inter-laboratory variability. In 2004 Hemker et al. came to the resolution 
that methods using fluorogenic substrates were more appropriate than stirred 
methods[36]. In 2011 Castoldi et al. focussed on the Calibrated Automated 
Thrombography (CAT). Basically, fluorogenic substrate is given to whole plasma in 
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microtiter plates and then thrombin generation is measured with a fluorometer and 
converted in thrombin generation curves. The advantage of CAT is the possibility to 
use platelet-rich plasma and so get results closer to the in vivo situation[18]. Current 
studies analysing thrombin generation in different contexts also use fluorogenic 
methods, especially the Calibrated Automated Thrombography[12, 23, 31, 32, 56, 84]. 
It is difficult to affirm which method is the best. More important is to standardise a 
method for all laboratories. For sure, RECA is an ultra-sensitive, ultra-specific method 
and has to be considered for this purpose. 
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